News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
Sanofi's venglustat granted priority review by FDA for type 3 Gaucher disease treatment. Potential first US therapy for neurological manifestations. Action date set for Nov 25, 2026 -
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat granted priority review by FDA for treating type 3 Gaucher disease. Potential first US therapy for neurological manifestations with target action date on November 25, 2026 -
-
-
-
